DMK Pharmaceuticals (DMK) EBITDA

Annual EBITDA

-$23.58 M
+$7.06 M+23.04%

December 1, 2022

Summary

Performance

1-Year Change

+23.04%

3-Year Change

+3.52%

5-Year Change

-4.39%

15-Year Change

-4.39%

DMK EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$766.40 K
DMK annual EBITDA is currently -3176.14% below its historical high of $766.40 thousand

3-Year Low

-$30.63 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2022
DMK previous annual earnings announcement was published on Dec 1, 2022

Next Annual Earnings Report Date

N/A
DMK next annual earnings announcement has not yet been scheduled

OtherDMKprofitabilitymetrics:

Annual Revenue

$4.76 M
DMK annual revenue is $4.76 million

Annual Net Income

-$26.48 M
DMK annual net profit is -$26.48 million

Annual EBIT

-$25.06 M
DMK annual earnings before interest & taxes is -$25.06 million

Annual EPS

-$12.60
DMK annual earnings per share is -$12.60

Quarterly EBITDA

-$1.64 M
+$5.23 M+76.13%

September 1, 2023

Summary

Performance

3-Month Change

+76.13%

1-Year Change

+57.66%

3-Year Change

+83.6%

5-Year Change

+79.68%

DMK Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$5.16 M
DMK quarterly EBITDA is currently -131.78% below its historical high of $5.16 million

3-Year Low

-$7.97 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2023
DMK previous earnings announcement was published on Sep 1, 2023

Next Quarterly Earnings Report Date

N/A
DMK next earnings announcement has not yet been scheduled

OtherDMKprofitabilitymetrics:

Quarterly Revenue

$9100.00
DMK quarterly revenue is $9100.00

Quarterly Net Income

-$1.39 M
DMK quarterly net profit is -$1.39 million

Quarterly EBIT

-$1.71 M
DMK quarterly earnings before interest & taxes is -$1.71 million

Quarterly EPS

-$0.20
DMK quarterly earnings per share is -$0.20

TTM EBITDA

-$16.72 M
+$2.23 M+11.78%

September 1, 2023

Summary

Performance

3-Month Change

+11.78%

1-Year Change

+31.29%

3-Year Change

+46.83%

5-Year Change

+31.59%

DMK TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$984.80 K
DMK TTM EBITDA is currently -1797.60% below its historical high of $984.80 thousand

3-Year Low

-$30.57 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2023
DMK previous earnings announcement was published on Sep 1, 2023

Next Quarterly Earnings Report Date

N/A
DMK next earnings announcement has not yet been scheduled

OtherDMKprofitabilitymetrics:

TTM Revenue

$3.62 M
DMK TTM revenue is $3.62 million

TTM Net Income

-$22.23 M
DMK TTM net profit is -$22.23 million

TTM EBIT

-$17.35 M
DMK TTM earnings before interest & taxes is -$17.35 million

TTM EPS

-$9.58
DMK TTM earnings per share is -$9.58

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$23.58 M
DMK annual EBITDA is -$23.58 million

Annual Net Income

-$26.48 M
DMK annual net profit is -$26.48 million

Annual Interest Expense

-
DMK annual interest expense value is unknown

Annual Income Tax

$2000.00
DMK annual income tax is $2000.00

Annual D&A

$1.48 M
DMK annual depreciation & amortization is $1.48 million

DMK EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+23.0%+57.7%+31.3%
3 y3 years+3.5%+83.6%+46.8%
5 y5 years-4.4%+79.7%+31.6%

DMK EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+29.9%at high+385.9%at high+82.9%
5 y5-yearat high+42.1%at high+725.4%at high+180.2%
alltimeall time-3176.1%+53.2%-131.8%+725.4%-1797.6%+180.2%

DMK Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2023
-
-$1.64 M(-76.1%)
-$16.72 M(-11.8%)
Jun 2023
-
-$6.87 M(+8.7%)
-$18.95 M(-5.5%)
Mar 2023
-
-$6.32 M(+234.2%)
-$20.05 M(-5.9%)
Dec 2022
-$23.58 M(-23.0%)
-$1.89 M(-51.2%)
-$21.30 M(-12.5%)
Sep 2022
-
-$3.87 M(-51.4%)
-$24.33 M(-3.6%)
Jun 2022
-
-$7.97 M(+5.3%)
-$25.25 M(+2.6%)
Mar 2022
-
-$7.57 M(+53.7%)
-$24.61 M(-19.5%)
Dec 2021
-$30.63 M(-8.6%)
-$4.92 M(+2.8%)
-$30.57 M(-17.2%)
Sep 2021
-
-$4.79 M(-34.6%)
-$36.94 M(-12.4%)
Jun 2021
-
-$7.32 M(-45.9%)
-$42.15 M(-10.0%)
Mar 2021
-
-$13.53 M(+19.8%)
-$46.84 M(+18.3%)
Dec 2020
-$33.51 M(+37.1%)
-$11.29 M(+12.9%)
-$39.60 M(+25.9%)
Sep 2020
-
-$10.00 M(-16.8%)
-$31.44 M(+13.4%)
Jun 2020
-
-$12.01 M(+91.0%)
-$27.72 M(+22.1%)
Mar 2020
-
-$6.29 M(+100.7%)
-$22.71 M(-7.1%)
Dec 2019
-$24.44 M(-32.3%)
-$3.13 M(-50.1%)
-$24.44 M(-27.4%)
Sep 2019
-
-$6.28 M(-10.3%)
-$33.68 M(-5.0%)
Jun 2019
-
-$7.00 M(-12.7%)
-$35.47 M(-5.0%)
Mar 2019
-
-$8.02 M(-35.2%)
-$37.34 M(+3.4%)
Dec 2018
-$36.12 M(+59.9%)
-$12.38 M(+53.4%)
-$36.12 M(+15.4%)
Sep 2018
-
-$8.07 M(-9.1%)
-$31.31 M(+7.2%)
Jun 2018
-
-$8.88 M(+30.6%)
-$29.20 M(+19.4%)
Mar 2018
-
-$6.80 M(-10.2%)
-$24.46 M(+8.3%)
Dec 2017
-$22.58 M(+6.2%)
-$7.57 M(+27.0%)
-$22.58 M(+16.4%)
Sep 2017
-
-$5.96 M(+44.1%)
-$19.41 M(+0.9%)
Jun 2017
-
-$4.13 M(-16.0%)
-$19.24 M(-3.9%)
Mar 2017
-
-$4.92 M(+12.1%)
-$20.02 M(-4.1%)
Dec 2016
-$21.26 M(+65.3%)
-$4.39 M(-24.2%)
-$20.87 M(+9.3%)
Sep 2016
-
-$5.79 M(+17.6%)
-$19.10 M(+16.7%)
Jun 2016
-
-$4.92 M(-14.7%)
-$16.37 M(+11.1%)
Mar 2016
-
-$5.77 M(+120.6%)
-$14.73 M(+14.5%)
Dec 2015
-$12.86 M(+56.8%)
-$2.61 M(-14.5%)
-$12.86 M(+25.5%)
Sep 2015
-
-$3.06 M(-6.8%)
-$10.25 M(+13.7%)
Jun 2015
-
-$3.28 M(-15.8%)
-$9.01 M(+11.4%)
Mar 2015
-
-$3.90 M(+113.4%)
-$8.09 M(+38.9%)
Dec 2014
-$8.20 M(-1170.2%)
-
-
Sep 2014
-
-$1.83 M(-22.5%)
-$5.83 M(+365.6%)
Jun 2014
-
-$2.36 M(+67.7%)
-$1.25 M(-366.0%)
Mar 2014
$766.40 K(-116.2%)
-$1.41 M(+509.3%)
$470.30 K(-52.2%)
Dec 2013
-
-$230.90 K(-108.4%)
$984.80 K(+1034.6%)
Sep 2013
-
$2.75 M(-530.6%)
$86.80 K(-103.0%)
Jun 2013
-
-$637.60 K(-28.5%)
-$2.94 M(-37.9%)
Mar 2013
-$4.73 M(-1.6%)
-$892.30 K(-21.0%)
-$4.73 M(-4.8%)
Dec 2012
-
-$1.13 M(+305.9%)
-$4.97 M(+2.9%)
Sep 2012
-
-$278.10 K(-88.6%)
-$4.83 M(-19.9%)
Jun 2012
-
-$2.43 M(+114.5%)
-$6.03 M(+25.3%)
Mar 2012
-$4.81 M(-22.7%)
-$1.13 M(+14.6%)
-$4.82 M(+0.3%)
Dec 2011
-
-$988.70 K(-33.2%)
-$4.80 M(-29.7%)
Sep 2011
-
-$1.48 M(+22.1%)
-$6.83 M(+5.8%)
Jun 2011
-
-$1.21 M(+8.5%)
-$6.46 M(+3.7%)
Mar 2011
-$6.23 M(+57.3%)
-$1.12 M(-63.0%)
-$6.23 M(-13.2%)
Dec 2010
-
-$3.02 M(+172.8%)
-$7.17 M(+48.1%)
Sep 2010
-
-$1.11 M(+12.5%)
-$4.84 M(+13.6%)
Jun 2010
-
-$983.30 K(-52.4%)
-$4.26 M(+7.7%)
Mar 2010
-$3.96 M
-$2.06 M(+200.2%)
-$3.96 M(+78.9%)
Dec 2009
-
-$687.70 K(+30.4%)
-$2.21 M(+24.0%)
Sep 2009
-
-$527.20 K(-22.4%)
-$1.78 M(+17.4%)
DateAnnualQuarterlyTTM
Jun 2009
-
-$679.70 K(+113.1%)
-$1.52 M(+29.3%)
Mar 2009
-
-$319.00 K(+23.1%)
-$1.18 M(-11.1%)
Dec 2008
-$1.32 M(-27.4%)
-$259.10 K(-1.1%)
-$1.32 M(-12.8%)
Sep 2008
-
-$262.00 K(-21.8%)
-$1.52 M(-8.7%)
Jun 2008
-
-$335.00 K(-28.0%)
-$1.66 M(-6.0%)
Mar 2008
-
-$465.00 K(+2.5%)
-$1.77 M(-3.1%)
Dec 2007
-$1.82 M(-58.3%)
-$453.60 K(+11.7%)
-$1.82 M(+31.5%)
Sep 2007
-
-$406.00 K(-7.9%)
-$1.39 M(-40.7%)
Jun 2007
-
-$441.00 K(-15.4%)
-$2.34 M(-16.4%)
Mar 2007
-
-$521.00 K(+2843.5%)
-$2.79 M(-34.0%)
Dec 2006
-$4.37 M(-1.0%)
-$17.70 K(-98.7%)
-$4.23 M(-35.1%)
Sep 2006
-
-$1.36 M(+51.0%)
-$6.52 M(-16.8%)
Jun 2006
-
-$898.00 K(-54.2%)
-$7.84 M(+340.2%)
Mar 2006
-
-$1.96 M(-14.8%)
-$1.78 M(-63.0%)
Dec 2005
-$4.41 M(-67.1%)
-$2.30 M(-13.9%)
-$4.81 M(-33.5%)
Sep 2005
-
-$2.68 M(-151.9%)
-$7.23 M(-6.7%)
Jun 2005
-
$5.16 M(-203.4%)
-$7.75 M(-50.8%)
Mar 2005
-
-$4.99 M(+5.6%)
-$15.75 M(+12.5%)
Dec 2004
-$13.42 M(+0.7%)
-$4.72 M(+47.9%)
-$14.00 M(+8.9%)
Sep 2004
-
-$3.19 M(+12.6%)
-$12.86 M(+3.2%)
Jun 2004
-
-$2.84 M(-12.6%)
-$12.46 M(-13.4%)
Mar 2004
-
-$3.25 M(-9.3%)
-$14.39 M(+4.4%)
Dec 2003
-$13.33 M(-14.8%)
-$3.58 M(+27.8%)
-$13.79 M(-5.0%)
Sep 2003
-
-$2.80 M(-41.3%)
-$14.51 M(+7.8%)
Jun 2003
-
-$4.77 M(+80.9%)
-$13.47 M(-6.8%)
Mar 2003
-
-$2.64 M(-38.8%)
-$14.45 M(-12.2%)
Dec 2002
-$15.65 M(-5.6%)
-$4.31 M(+145.2%)
-$16.46 M(-2.5%)
Sep 2002
-
-$1.76 M(-69.5%)
-$16.87 M(-12.6%)
Jun 2002
-
-$5.75 M(+23.9%)
-$19.30 M(+7.8%)
Mar 2002
-
-$4.64 M(-1.7%)
-$17.90 M(+2.5%)
Dec 2001
-$16.57 M(+52.2%)
-$4.72 M(+12.9%)
-$17.46 M(+5.2%)
Sep 2001
-
-$4.18 M(-3.9%)
-$16.60 M(+7.8%)
Jun 2001
-
-$4.35 M(+3.5%)
-$15.40 M(+10.7%)
Mar 2001
-
-$4.21 M(+9.1%)
-$13.91 M(+19.0%)
Dec 2000
-$10.89 M(+15.2%)
-$3.86 M(+29.0%)
-$11.69 M(+12.5%)
Sep 2000
-
-$2.99 M(+4.3%)
-$10.39 M(+7.4%)
Jun 2000
-
-$2.86 M(+44.6%)
-$9.67 M(+5.5%)
Mar 2000
-
-$1.98 M(-22.5%)
-$9.17 M(-7.6%)
Dec 1999
-$9.45 M(+11.7%)
-$2.55 M(+12.3%)
-$9.93 M(+3.0%)
Sep 1999
-
-$2.27 M(-3.5%)
-$9.64 M(-0.3%)
Jun 1999
-
-$2.36 M(-14.0%)
-$9.67 M(-1.5%)
Mar 1999
-
-$2.74 M(+20.8%)
-$9.81 M(+13.2%)
Dec 1998
-$8.47 M(+84.1%)
-$2.27 M(-1.4%)
-$8.67 M(+7.0%)
Sep 1998
-
-$2.30 M(-8.0%)
-$8.10 M(+20.9%)
Jun 1998
-
-$2.50 M(+56.3%)
-$6.70 M(+28.8%)
Mar 1998
-
-$1.60 M(-5.9%)
-$5.20 M(+13.0%)
Dec 1997
-$4.60 M(+24.3%)
-$1.70 M(+88.9%)
-$4.60 M(+24.3%)
Sep 1997
-
-$900.00 K(-10.0%)
-$3.70 M(-2.6%)
Jun 1997
-
-$1.00 M(0.0%)
-$3.80 M(+2.7%)
Mar 1997
-
-$1.00 M(+25.0%)
-$3.70 M(+5.7%)
Dec 1996
-$3.70 M(+311.1%)
-$800.00 K(-20.0%)
-$3.50 M(+2.9%)
Sep 1996
-
-$1.00 M(+11.1%)
-$3.40 M(+30.8%)
Jun 1996
-
-$900.00 K(+12.5%)
-$2.60 M(+136.4%)
Mar 1996
-
-$800.00 K(+14.3%)
-$1.10 M(+450.0%)
Dec 1995
-$900.00 K
-$700.00 K(+250.0%)
-$200.00 K(-140.0%)
Sep 1995
-
-$200.00 K(-133.3%)
$500.00 K(-28.6%)
Jun 1995
-
$600.00 K(+500.0%)
$700.00 K(+600.0%)
Mar 1995
-
$100.00 K
$100.00 K

FAQ

  • What is DMK Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for DMK Pharmaceuticals?
  • What is DMK Pharmaceuticals annual EBITDA year-on-year change?
  • What is DMK Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for DMK Pharmaceuticals?
  • What is DMK Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is DMK Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for DMK Pharmaceuticals?
  • What is DMK Pharmaceuticals TTM EBITDA year-on-year change?

What is DMK Pharmaceuticals annual EBITDA?

The current annual EBITDA of DMK is -$23.58 M

What is the all time high annual EBITDA for DMK Pharmaceuticals?

DMK Pharmaceuticals all-time high annual EBITDA is $766.40 K

What is DMK Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, DMK annual EBITDA has changed by +$7.06 M (+23.04%)

What is DMK Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of DMK is -$1.64 M

What is the all time high quarterly EBITDA for DMK Pharmaceuticals?

DMK Pharmaceuticals all-time high quarterly EBITDA is $5.16 M

What is DMK Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, DMK quarterly EBITDA has changed by +$2.23 M (+57.66%)

What is DMK Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of DMK is -$16.72 M

What is the all time high TTM EBITDA for DMK Pharmaceuticals?

DMK Pharmaceuticals all-time high TTM EBITDA is $984.80 K

What is DMK Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, DMK TTM EBITDA has changed by +$7.61 M (+31.29%)